JonesResearch downgraded Lumos Pharma (LUMO) to Hold from Buy with a price target of $4.25, down from $20. The company’s definitive merger with Double Point Ventures to go private a via tender offer at $4.25 per share plus a contingent value right at a $38M is done a “disappointing” valuation, the analyst tells investors in a research note. The firm says the CVR is also disappointing as it would have liked to see payments based on regulatory milestones. While the valuation is disappointing, Lumos Pharma’s cash runway limits better alternatives, contends JonesResearch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LUMO:
- Lumos Pharma reports Q3 net loss $7.5M
- Lumos Pharma enters merger agreement with Double Point Ventures to go private
- Lumos Pharma initiated with a Buy at EF Hutton
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
